WHAT THE STUDY ACTUALLY SAYS

The Lancet's ultra-processed food series makes a displacement argument

Three papers published on 18 November argue the harm is not one ingredient but the replacement of whole-food diets. The evidence they assemble is strongest for diet quality and weakest where causation is hardest.

On 18 November The Lancet published a three-part Series on ultra-processed foods. Series papers are not primary research: they are commissioned syntheses that argue a position, and they should be read that way. This one argues a specific position that is worth separating from the general noise around the topic.

The argument is about displacement, not additives

The first paper sets out three hypotheses and assesses each in turn, combining narrative and systematic reviews with original analyses and meta-analyses [s1].

The first hypothesis is that a dietary pattern based on ultra-processed foods is globally displacing long-established diets centred on whole foods and their culinary preparation as dishes and meals. The paper reports this as supported by decades of national food intake and purchase surveys plus recent global sales data [s1].

The second is that this pattern degrades diet quality, particularly in relation to chronic disease prevention. The paper reports this as confirmed by national food intake surveys, large cohorts, and interventional studies, citing gross nutrient imbalances; overeating driven by high energy density, hyper-palatability, soft texture, and disrupted food matrices; reduced intake of health-protective phytochemicals; and increased intake of toxic compounds, endocrine disruptors, and potentially harmful classes and mixtures of food additives [s1].

The third is that the pattern raises the risk of multiple diet-related chronic diseases. The paper reports this as substantiated by more than 100 prospective studies, meta-analyses, randomised controlled trials, and mechanistic studies, covering adverse outcomes across nearly all organ systems [s1].

The framing matters. The claim is not that a particular emulsifier or a particular sweetener causes disease. It is that a whole dietary pattern is replacing another, and that the replacement is the exposure [s1].

Where that argument is strong and where it is not

The three hypotheses are not equally easy to test, and the paper's own descriptions track that. Displacement is an observation about what people buy and eat, and food purchase data can show it. Diet quality deterioration is measurable in intake surveys and in feeding studies. Disease causation is the hardest of the three, because the dominant evidence base is prospective cohorts, where people who eat the most ultra-processed food differ from people who eat the least in many ways at once.

The paper's own accounting notes that the third hypothesis rests on more than 100 studies of mixed design, including randomised trials and mechanistic work alongside the cohorts [s1]. A reader should hold the three claims at different confidence levels rather than as one verdict.

The two policy papers

The second Series paper proposes government policies aimed at halting and reversing the rise of ultra-processed foods worldwide [s2]. Its central move is to argue that existing policy — which has mainly focused on reducing consumption of foods high in added fats, sugar, and sodium, many of which are ultra-processed — should be strengthened and expanded to address a broader set of food system drivers [s2].

It organises those into four domains: ultra-processed food products; ultra-processed food environments; manufacturers, fast-food corporations, and supermarket retailers; and food supply chains [s2]. It also examines policies to protect, incentivise, and support diets based on fresh and minimally processed foods, particularly for lower-income households [s2]. The paper is explicit that which actions a government prioritises will depend on that country's level of ultra-processed food consumption and other country-specific issues [s2].

The third paper is the most political of the three. It argues the ultra-processed food industry is a key driver of the problem, that the higher profitability of these products relative to other foods financially incentivises the business model, and that the main barrier to policy is the industry's corporate political activities — direct lobbying, infiltrating government agencies, litigation, promoting corporate-friendly governance models, and manufacturing scientific doubt [s3]. It draws an explicit parallel to tobacco control decades ago [s3].

Its proposed responses include disrupting the ultra-processed business model, protecting food governance from corporate interference, implementing conflict of interest safeguards in policy making and research, building advocacy coalitions, and ensuring a just transition to low-UPF diets [s3].

How to read a Series

A Lancet Series is advocacy grounded in evidence, commissioned to move a policy debate. That is a legitimate genre and it is not the same as a trial report. The strongest reason to take this one seriously is the breadth of the evidence assembled in the first paper [s1]; the strongest reason for caution is that the third paper's argument about corporate power, whatever its merits, is political analysis rather than epidemiology [s3].

The definitional question also remains live. "Ultra-processed" is a category defined by processing rather than by nutrient content, and how a food gets classified determines what any study of it finds. None of the three papers resolves that; the Series proceeds on the classification as it stands.

This article is informational and does not constitute medical or dietary advice.

Sources

Sources

  1. Ultra-processed foods and human health: the main thesis and the evidenceThe Lancet , November 18, 2025
  2. Policies to halt and reverse the rise in ultra-processed food production, marketing, and consumptionThe Lancet , November 18, 2025
  3. Towards unified global action on ultra-processed foods: understanding commercial determinants, countering corporate power, and mobilising a public health responseThe Lancet , November 18, 2025

More on

Related coverage